Latest Conference Articles

Researchers push for transparency between health care professionals and patients with diabetes about the safety and efficacy of the influenza vaccine

In part 1 of a Q&A, Elena Christofides, MD highlights important discussions surrounding ADA 2021, including cardiometabolic medicine and risk factors for T1D.

Investigative ORMD-0701 has potential to regulate the insulin-glucagon balance in patients.

Changes in physical activity and diet may be main cause for worsening of diabetes control.

Data show similar family impact and distress scores at baseline and 3-months, highlighting continued impact of COVID-19 on T1D population.

A longer time spent in hypoglycemia over a 24-hour period was associated with disrupted sleep among children with type 1 diabetes.

Matthew Budoff, MD highlights his own preferred methods of treatment and what might need to be done to help doctors and patients through the process.

The study shows a reduction in hemoglobin and a reduced risk of hypoglycemia in participants.

Of the two diabetes treatments included in the study, patients with Gla-300 had lower recorded total health costs and greater commitment to treatment.

Data show 66% of healthcare professionals reported greater confidence in prescribing SGLT2i, while 55% reported greater confidence in prescribing GLP-1.

Researchers found a significant interaction between SGLT2 inhibitors based on age and eGFR.

Fluid regulation is important to the prevention of heart failure.

Data show 37.5% of patients in study were found to have moderate to severe DD, with an average score of ≥2.

eGFR improved by 10.8% and creatinine decreased by 6.8% in patients who received PIT procedures.

Data show consistent benefit of finerenone on kidney and CV outcomes in patients with CKD and T2D, regardless of SGLT-2i use.

The COVID-19 pandemic has increased the usage of telemedicine tools in all medical fields.

Children treated with SSRIs and SGAs concurrently demonstrate higher waist circumference, BMI, and plasma total cholesterol compared to those on monotherapy.

Over half of patients attained target A1C <7%. while a third of patients attained target A1C of <8%.

Overweight/obese patients with elevated fasting blood glucose generally present with higher degrees of insulin resistance, inflammation, adverse cardiovascular disease risk profile.

New findings show patients were able to more than halve type 2 diabetes medication while improving diabetic and cardiovascular parameters in 8 weeks.

New SUPRASS-2 findings show the dual GIP/GLP-1 agonist provided superior type 2 diabetes management outcomes at 3 different doses.

Data show no evidence of increased risk of adverse events in patients aged ≥80 years, compared to patients aged 70 - 79 years.

A comparison of 3 standard dietary strategies for weight and glycemia control showed no difference in exercise metrics.

The study author joins to highlight new ADA 2021 findings showing rivaroxaban's benefit for a subpopulation of diabetic patients.

The ADA study represents the first randomized head-to-head trial directly compareding an FRC with a remix insulin analog in a population of adults with suboptimally controlled type 2 diabetes on basal insulin plus OADs.

New data presented at ADA 2021 show GLP-1RA treatment is budget neutral in comparison to SoC, citing lower inpatient and outpatient cost.